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Natural killer T (NKT) cells respond to a variety of
CD1d-restricted antigens (Ags), although the basis
for Ag discrimination by the NKT cell receptor (TCR)
is unclear. Here we have described NKT TCR fine
specificity against several closely related Ags,
termed altered glycolipid ligands (AGLs), which
differentially stimulate NKT cells. The structures of
five ternary complexes all revealed similar docking.
Acyl chain modifications did not affect the interac-
tion, but reduced NKT cell proliferation, indicating
an affect on Ag processing or presentation. Con-
versely, truncation of the phytosphingosine chain
caused an induced fit mode of TCR binding that
affected TCR affinity. Modifications in the glycosyl
head group had a direct impact on the TCR interac-
tion and associated cellular response, with ligand
potency reflecting the t1/2 life of the interaction.
Accordingly, we have provided a molecular basis
for understanding how modifications in AGLs can
result in striking alterations in the cellular response
of NKT cells.
INTRODUCTION
Natural killer T (NKT) cells express specific ab T cell receptors
(TCRs) that recognize glycolipid antigens (Ag) presented by the
nonclassical MHC class I molecule CD1d (reviewed in Godfrey
et al., 2004). Most human NKT cells express an invariant Va24-
Ja18 TCRa chain, paired with a Vb11 TCRb chain, whereas
murine NKT cells similarly express an invariant Va14-Ja18
TCRa chain, paired with one of three different TCRb chain Vgenes (Vb8, Vb7, Vb2) of which Vb8.2, the homolog of Vb11,
is the most common (reviewed in Bendelac et al., 2007; Godfrey
et al., 2008). Upon activation, NKT cells rapidly produce an
array of cytokines and can influence immune outcomes in a
broad range of settings, including microbial immunity, tumor
immunity, autoimmunity, and allergy (reviewed in Godfrey
et al., 2004). a-galactosylceramide (a-GalCer) (Kawano et al.,
1997), a synthetic a-glycolipid widely used for activating NKT
cells, is considered as a surrogate for a largely unknown reper-
toire of natural NKT ligands and is now used experimentally in
preclinical and clinical translational studies as a potent NKT
cell agonist (reviewed in Brutkiewicz, 2006).
The structures of human and mouse NKT TCRs, unliganded
and in complex with CD1d-a-GalCer, have been determined,
as well as the mouse NKT TCR in complex with a-galactosyl-
diacylglycerol (a-GalDAG) (Borg et al., 2007; Gadola et al.,
2006; Kjer-Nielsen et al., 2006; Li et al., 2010; Pellicci et al.,
2009). These ternary complexes showed a conserved docking
strategy that differs from all known TCR-peptide-MHC interac-
tions (reviewed in Godfrey et al., 2008). The invariant NKT
TCRa chain dominates this interaction, with the CDR1a loop
interacting solely with the lipid Ag, whereas the CDR3a loop
plays a central role, contacting CD1d and the lipid Ag (Borg
et al., 2007; Pellicci et al., 2009). The role of the human Vb11
and the homologous mouse Vb8.2 chain is essentially restricted
to the CDR2b loop that interacts with CD1d. Comparison of the
mouse Vb8.2 and Vb7 NKT TCR-CD1d-a-GalCer complexes
shows similar docking, although conformational changes alter
some of the contacts between the TCRa chain with CD1d-a-
GalCer, indicating that differential Vb chain usage could impact
on CD1d-restricted Ag specificity (Pellicci et al., 2009).
NKT TCRs can bind an array of different lipid-based Ags
in complex with CD1d, including bacteria-derived lipid Ags
such as a-glycuronosylceramides, a-galactosyl-diacylglycerols,
and phosphatidyl-inositol mannosides, and mammalian lipidImmunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc. 327
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viewed in Brutkiewicz, 2006; Godfrey et al., 2010). Structural
studies have provided insight into howCD1d can present natural
and synthetic Ags (reviewed in Godfrey et al., 2010), although it is
mostly unknown at the structural level how alterations in the
CD1d-Ag landscape affect NKT TCR recognition. Some insight
into the adaptability of the NKT TCR to recognize distinct
CD1d-restricted Ags arose from NKT TCR mutagenesis experi-
ments that underscored the importance of the CDR1a, CDR3a,
and CDR2b loops, yet also showed that someNKT TCR residues
that contact Ag were not essential (Borg et al., 2007; Florence
et al., 2009; Mallevaey et al., 2009; Pellicci et al., 2009; Scott-
Browne et al., 2007; Wun et al., 2008). Further, glycolipids with
different lipid tail lengths can alter the affinity for the NKT TCR,
with the mechanism speculated to occur through alterations of
the F0-pocket of CD1d, a major point of contact with the NKT
TCR (McCarthy et al., 2007; Sullivan et al., 2010). Whereas the
NKT TCRa chain is invariant, the b chain plays a role in deter-
mining thresholds of Ag reactivity, and this effectively enables
some NKT TCRs to differentiate between Ags (Mallevaey et al.,
2009). Furthermore, the composition of the CDR3b loop might
determine CD1d autoreactivity to self-Ags (Matulis et al., 2010;
Mallevaey et al., 2011, this issue). Nevertheless, how the NKT
TCR can recognize distinct self- and nonself-CD1d-Ags and
possesses the capacity to discriminate between closely related
Ags remains unclear (Gapin, 2010).
Altered peptide ligands (APLs) can dramatically affect MHC-
restricted T cell-mediated biological outcomes (Sloan-Lancaster
and Allen, 2003), yet cause only slight conformational readjust-
ments at the TCR-pMHC-I interface (Baker et al., 2000; Degano
et al., 2000). Paralleling this, numerous synthetic agonist analogs
of a-GalCer have been described that differ in the structure of the
glycosyl head group and/or lipid tails (reviewed in Venkatasw-
amy and Porcelli, 2010). These represent the glycolipid equiva-
lent of APLs and have remarkably distinct effects on NKT cell
function. Some analogs (such asOCH andC20:2) have the ability
to promote T helper 2 (Th2) cell-biased responses (Yu et al.,
2005), whereas others (such as a-C-glycoside) (Schmieg et al.,
2003) promote T helper 1 (Th1) cell-biased responses. Thus,
studies with glycolipid analogs demonstrate the feasibility of
using these to manipulate the NKT cell response, which can
translate to more tailored NKT cell-based therapies (reviewed
in Cerundolo et al., 2009). However, to achieve more targeted
NKT-based therapeutics requires a greater understanding of
the molecular basis of antigenic modulation of the NKT cell
response. Here we report the structural and functional correlates
of NKT TCR recognition of a series of closely related CD1d-
restricted altered glycolipid ligands (AGLs). Our findings provide
a systematic analysis of the mechanisms by which NKT TCR
interactions with closely related glycolipid ligands presented by
CD1d influences fine specificity and functional responses.
RESULTS
Affinity Hierarchy for the Glycolipid Antigens
a-GalCer, also known as KRN7000, is the prototypical agonist
for NKT cells that possesses an 18C phytosphingosine and
a 26C acyl chain (Kawano et al., 1997). Because many analogs
of this Ag have been generated that promote distinct NKT cell328 Immunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc.responses (reviewed in Venkataswamy andPorcelli, 2010), a crit-
ical question is whether the altered functionality is determined by
their differential impact on TCR binding. We have investigated
a panel of 10 different AGLs (Figures 1A–1J): (1) a-GalCer, (2)
OCH, with C9 phytosphingosine and C24:0 acyl chains (Miya-
moto et al., 2001); (3) C20:2, a C20 acyl chain and cis-diunsatu-
ration at C11 and 14 (Yu et al., 2005); (4) a-GlcCer, identical
ceramide component to C20:2, but a-linked glucosyl head group
(Jervis et al., 2010); (5) 30,400-deoxy-a-GalCer, both the 30-OH of
the sugar and the 40-OH of the sphingoid base are removed (Raju
et al., 2009); and (6) 40,400-deoxy-a-GalCer, both the 40-OH of the
sugar and the 40-OH of the sphingoid base are removed (Raju
et al., 2009). To control for the dual modifications separately,
we synthesized a new AGL (7), 40-deoxy-a-GalCer, with a
40-deoxy-sugar but retaining the 40-OH group on the sphingoid
base. For functional studies (below) we also analyzed (8) the
400-deoxy-a-GalCer AGL (with an a-Gal sugar, but lacking the
40-OH on the sphingoid base). We also included (9) a-GalCer
(C24) and (10) a-GlcCer (C24), both with 24C acyl and 18C sphin-
gosine chains, further enabling a direct comparison of the effect
of modifying the orientation of the 40-OH position of the sugar.
First, we determined the affinity of the interaction between the
mouse Vb8.2 NKT TCR and the CD1d-AGL complexes by using
surface plasmon resonance (SPR). Purified mouse CD1d was
loaded with the eight individual AGLs or a-GalCer as a positive
control. The affinity as determined by responses at equilibrium
(equilibrium dissociation constant, KDeq) of the TCR for
mCD1d-a-GalCer was 0.059 mM, similar to previous reports.
In contrast, the NKT TCR affinity for some, but not all, of the
CD1d-AGL complexes deviated from that of CD1d-a-GalCer
(Figures 2A–2I; Table S1 available online). For example, the
affinity of the NKT TCR-CD1d-a-GalCer (C20:2) interaction, at
0.068 mM (Figure 2C), and the NKT TCR-CD1d-a-GalCer (C24)
interaction (KDeq = 0.049 mM) (Figure 2H) was essentially identical
to that of the positive control, indicating that the modifications to
the extent of acyl chain saturation and truncation did not impact
on NKT TCR affinity. This result is consistent with earlier studies
based on a-GalCer-CD1d tetramer versus C20:2-CD1d tetramer
dissociation from cells (Im et al., 2009). The CD1d-OCH complex
exhibited 0.3 mM affinity for the NKT TCR (Figure 2B), approx-
imately 20%of the affinity of the NKT TCR-CD1d-a-GalCer inter-
action. Although this is broadly consistent with previous avidity
studies with CD1d tetramer dissociation, this affinity was still
higher than expected fromearlier studies (Im et al., 2009; Sullivan
et al., 2010). This discrepancy may reflect differences between
molecular affinity and tetramer avidity. Nonetheless, given that
composition of the solvent-exposed sugar is identical between
OCH and a-GalCer, these data suggested that the modified
sphingosine chain, which was buried within the F0-pocket, can
indirectly affect head group presentation or CD1d conformation
and therefore NKT TCR recognition. The affinity of the NKT TCR-
CD1d-30,400-deoxy-a-GalCer interaction, at 0.2 mM (Figure 2E),
was only approximately 30% of the affinity compared to the
positive control, suggesting that the 30-OH moiety of the galac-
tosyl headgroup influenced, but was not critical for, the interac-
tion. In contrast, the a-GlcCer (C24) and the a-GlcCer (C20:2)
exhibited a much reduced affinity (KDeq of 0.55 mM and
0.68 mM, respectively), suggesting that the 40-OH moiety was
a key determinant in the NKT TCR interaction (Figures 2D and
Figure 1. Schematic of a-GalCer and the AGLs
(A) a-GalCer, (B) OCH, (C) a-GalCer (C20:2), (D) a-GlcCer (C20:2), (E)
30,400-deoxy-a-GalCer, (F) 40,400-deoxy-a-GalCer, (G) 40-deoxy-a-GalCer, (H)
400-deoxy-a-GalCer, (I) a-GalCer (C24), and (J) a-GlcCer (C24).
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(Figures 2F and 2G), which also differ from a-GalCer via modifi-
cations at the 40-OH position on the sugar, also exhibited a much
reduced affinity, at 0.5 mM. Thus, the 40-OH moiety on the
galactose headgroup was a key determinant in the NKT TCRinteraction, and furthermore, modification of the 400-OH group
on the sphingosine chain did not impact on the lower-affinity
NKT TCR interaction with these AGLs.
Given that the affinity of the NKT TCR-CD1d-Ag interaction
may not necessarily correlate with ligand potency, we also deter-
mined the kinetic rate constants of these interactions (Figures
2A–2I). There was a very good correlation between the KD calcu-
lated by kinetic and equilibrium analyses and the residual plots,
and low c2 values indicated that the kinetic rate constants were
measured accurately. In comparison to the association and
dissociation rate constants typical of TCR-pMHC interactions
(van der Merwe and Davis, 2003), the NKT TCR engages
CD1d-AGL complexes with fast on rates (ka) and slow off rates
(kd), with a long t1/2 life of approximately 20 s for the NKT TCR-
CD1d-a-GalCer-positive control interaction. AGLs with modifi-
cations in the acyl tail did not appreciably affect the ka or kd of
the interaction, whereas OCH impacted negatively on the asso-
ciation constant, which is suggestive of an induced fit mecha-
nism for TCR-CD1d-OCH ligation. Interestingly, the AGLs with
modifications in the glycosyl headgroup had a greater effect on
the off rate than the on rate, with the off rate increasing by up
to a factor of 10, and as such the t1/2 life of these interactions
were markedly shorter. Thus, these AGLs did not impact on
the formation of the NKT TCR-CD1d-AGL complex, but resulted
in less stable complexes being formed.
In summary, the structural modifications represented by these
CD1d-AGL complexes showed different effects on the affinity of
the NKT TCR interaction, with the following hierarchical order:
a-GalCer = a-GalCer (C20:2) = a-GalCer (C24) > 30,400-deoxy >
OCH > 40-deoxy = 40,400-deoxy = a-GlcCer (C20:2) = a-GlcCer
(C24). When the t1/2 life was used as a guide, this order was
preserved, with the exception of OCH, which had a markedly
longer half life when compared to that of the 30,400-deoxy AGL.
NKT Cell-Proliferative Response Shows a Contrasting
Hierarchy to Affinity Measurements
To investigate the relationship between the affinity of the AGLs
and their ability to induce NKT cell proliferation, the AGLs were
tested in an in vitro assay with carboxyfluorescein diacetate suc-
ciniimidyl ester (CFSE)-labeled, NKT cell-enriched thymocytes
cocultured with splenocytes derived from Tcra-Jtm1Tg mice
(Ja18/) as a source of Ag-presenting cells (APC) (Figures 3A
and 3B). Structural variations within the ceramide component
had the greatest impact on NKT cell proliferation, especially
evident at the low dose of 1 ng/ml. At this concentration, the
AGLs with nontruncated sphingosine and acyl chains all
produced robust proliferative responses. OCH also induced
proliferation at 1 ng/ml; however, this was consistently weaker
in comparison to the nontruncated AGLs. The major difference
between OCH and a-GalCer is the truncated C9 instead of C18
phytosphingosine chain, although OCH also has a slightly
shorter C24 acyl chain. The reduced NKT cell proliferation with
OCH appeared to be due to the phytosphingosine chain trunca-
tion because the C24 acyl chain variant of a-GalCer drove prolif-
eration to a similar extent to C26 a-GalCer. In contrast, the AGLs
containing two double bonds within the acyl chain (C20:2 and
a-GlcCer C20:2) barely induced NKT cell proliferation at 1 ng/ml.
They were, however, able to induce proliferation at a higher
dose (100 ng/ml) to a similar degree as their fully saturatedImmunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc. 329
Figure 2. Analysis of the Interaction between Vb8.2 NKT TCR and the CD1d Analogs as Assessed by Surface Plasmon Resonance
SPR sensograms showing the interaction between Vb8.2 NKT TCR and CD1d loaded with (A) a-GalCer, (B) OCH, (C) C20:2, (D) a-GlcCer, (E) 30,400-deoxy
a-GalCer, (F) 40,400-deoxy-a-GalCer, (G) 40-deoxy-a-GalCer, (H) a-GalCer (C24), or (I) a-GlcCer (C24). NKT TCR were injected over streptavidin-immobilized
CD1d-Ag and simultaneously over a control cell containing unloadedCD1d. Top: Sensograms show the binding (response units, RU) of increasing concentrations
of TCR to CD1d-Ag after baseline subtraction, displaying data points overlaid with curve fits. Bottom: Saturation plots demonstrating equilbrium binding of NKT
TCR to immobilized CD1d-Ag. The affinities derived by equilibrium analysis (KDeq) were equivalent to those derived by kinetic analysis.
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saturation within the acyl chain can have an impact on the effi-
cacy of glycolipid ligands as NKT cell agonists. In further support
of this, a-GlcCer with a C24 saturated acyl chain induced similar
NKT cell proliferation to a-GalCer with the C24 acyl chain. Given
that the hierarchy in terms of proliferative response is clearly
different from the affinity data, this suggested that the potency
of the AGLs for inducing proliferation of NKT cells did not corre-
late precisely with the affinity or kinetics of the NKT TCR interac-330 Immunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc.tions. This implied that other factors besides the equilibrium
binding affinity or kinetics of the NKT TCR can contribute to
the biological responses of NKT cells. This is consistent with
reports showing that APC processing and presentation can
vary for different glycolipid ligands, with some, such as
a-GalCer, being more dependent on CD1d internalization, lyso-
somal processing, and re-expression in the context of plasma
membrane lipid rafts than others, such as OCH and C20:2 (Bai
et al., 2009; Im et al., 2009; Sullivan et al., 2010). Therefore, we
AB
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Figure 3. NKT Cell-Proliferative Response to AGLs
(A and B) CFSE-labeled thymocytes enriched for NKT cells were cultured for
3 days with glycolipid-pulsed Tcra-Jtm1Tg (Ja18/) splenocytes.
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the different analogs in the absence of APCs. This approach was
used to assess the activation of an NKT cell hybridoma (not
shown), as well as proliferation of freshly isolated NKT cells (Fig-
ure 3C). In both cases, the hierarchy of the response was clearly
distinct to that observed when APCs were used and correlated
more closely with the affinity and t1/2 life of the ligands as deter-
mined by our SPR experiments. Collectively, these studies
support the concept that whereas TCR affinity for different
AGLs can influence NKT cell proliferation, differential Ag presen-
tation of these ligands appears to be a major factor in deter-
mining the threshold of the proliferative response.
Cytokine Response Correlates with Affinity Hierarchy
Whereas NKT cells are capable of producing a broad range of
cytokines in response to a-GalCer (reviewed in Godfrey et al.,
2004), the amounts and ratio of the different cytokines produced
may be modulated in response to different glycolipid AGLs (Im
et al., 2009). Therefore, we tested cells and cell supernatants
from similar cultures to those shown in Figures 3A and 3B for
cytokine production. IFN-g production by NKT cells was as-
sessed by intracellular cytokine staining (ICS) whereas the
production of IFN-g, IL-4, IL-13, and IL-17 within the culture
supernatant was determined with a cytometric bead array
(CBA) assay after 8 hr stimulation with each of the AGLs (Figures
4A and 4B). Cytokine assays were tested after stimulation with
the higher dose (100 ng/ml) at which proliferative responses to
the AGLs were all comparable (Figures 3A and 3B). Interestingly,
cytokine production by NKT cells did not correlate with prolifer-
ative potential for the AGLs under similar culture conditions.
For example, the AGLs with unmodified galactose residues
(a-GalCer, 400-deoxy-a-GalCer, C20:2, OCH, and a-GalCer
(C24)) induced the highest percentages of IFN-g-producing
NKT cells, whereas a-GlcCer (C20:2) repeatedly induced the
least IFN-g production of all and a-GlcCer (C24) was only
marginally better at inducing IFN-g production. The AGLs with
the modified galactose moieties (30,400-deoxy-, 40,400-deoxy-a-
GalCer, and 40-deoxy-a-GalCer) were also less potent inducers
of IFN-g production from NKT cells in comparison to a-GalCer,
despite a comparable capacity to induce NKT cell proliferation
(Figure 4A). A similar pattern of cytokine production was
observed for IFN-g, IL-4, IL-13, and IL-17 in the culture superna-
tants in response to the different AGLs as measured by CBA
(Figure 4B). Although some AGLs, such as OCH and C20:2,
are considered to be Th2 cell-biasing Ags, this was not apparent
in our assays. However, the Th2 cell-biasing capacity of these
agents is considered to be more a reflection of the differential
ability of these ligands to promote downstream IFN-g production
by bystander cells such as NK cells (Sullivan et al., 2010) rather(A) A selection of representative flow cytometry profiles showing percent
proliferated cells based on decreased CFSE intensity of a-GalCer-CD1d
tetramer+ NKT cells at each AGL dose.
(B) Graph depicts percentage divided cells (mean ± SEM) from two to six inde-
pendent experiments carried out as above.
(C) MACS-enriched CD1d-a-GalCer tetramer+ thymic NKT cells (23 104) were
CFSE labeled and cultured in plates precoated with either 10 or 1 mg/ml
CD1d-glycolipid complex. After 72 hr, CFSE dilution was measured by flow
cytometry. Graphs depict the percentage of divided NKT cells ± SEM of
n = 3 replicates per group from a single experiment.
Immunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc. 331
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Figure 4. NKT Cell Cytokine Response to
AGLs
(A and B) Thymocytes enriched for NKT cells were
cultured for 8 hr with Tcra-Jtm1Tg (Ja18/) spleno-
cytes previously pulsedwith glycolipid (100 ng/ml).
(A) The percentage of IFN-g+ a-GalCer-CD1d
tetramer+ NKT cells was detected by ICS. Data
are representative of four similar experiments.
GolgiStop (BD Biosciences) was added for the
last 4 hr.
(B) Culture supernatants were collected at 8 hr and
cytokine amounts were quantified via CBA (BD
Biosciences). Data are taken from one of at least
three representative experiments (n = 5 replicates),
graphs depict mean and SEM.
(C) Supernatants from cells stimulated by plate-
bound CD1d-glycolipid complex at 10 mg/ml
dose, as described in Figure 3C, were harvested
at 72 hr and cytokines analyzed by CBA. Graphs
depict the concentration of cytokines ± SEM of
n= 3 replicates per group froma single experiment.
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direct analysis of cytokine production by NKT cells by ICS at 2
and 6 hr after in vivo challenge with OCH fails to reveal a Th2
cell bias by the NKT cells directly, when compared to a-GalCer
(Sullivan et al., 2010). When we compared serum cytokines 2
and 20 hr after in vivo treatment with a-GalCer, OCH, and
C20:2, the ratio of IL-4 to IFN-g was similar to previous reports,
showing that a-GalCer provided a more sustained IFN-g
response at 20 hr compared to C20:2 and OCH (Figure S1).
These data demonstrated that, in contrast to the proliferation
of fresh NKT cells in response to the different AGLs presented
by APCs, cytokine production by NKT cells in this assay broadly
reflected the TCR affinity of these ligands. A similar pattern of
cytokine production was detected in culture supernatants that
were harvested from a plate-bound CD1d-AGL stimulation
assay (Figure 4C).
Structures of the NKT TCR-CD1d-AGL Complexes
To address the structural basis of the fine specificity of the NKT
TCR, we determined the structure of five NKT TCR-CD1d
complexes containing different AGLs, namely OCH, C20:2,
a-GlcCer, 30,400-deoxy-a-GalCer, and 40,400-deoxy-a-GalCer
(Figure 5; Figure S2, Table S2). These complexes all crystallized
in the same space group with similar unit cell dimensions, and
therefore any structural differences observed can be attributed
to the impact of the specific AGL.
In all five complexes, the NKT TCR adopted the characteristic
docking mode initially observed for the NKT TCR-CD1d-a-
GalCer complex (Borg et al., 2007; Pellicci et al., 2009), indi-332 Immunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc.cating a conserved footprint without any
repositioning of the NKT TCR caused
by the AGLs (Figures 5A–5F). For four
of the complexes (OCH, C20:2, 30,400-
deoxy-, and 40,400-deoxy-a-GalCer), the
buried surface area (BSA) upon ligation
was 740–790 A˚2, which compares closely
to the BSA value of 760 A˚2 at the NKT
TCR-CD1d-a-GalCer interface (Figures5A–5C, 5E, and 5F). Within the footprints of these four
complexes, the a chain contributed approximately three times
more BSA than did the b chain, in which the Va14- and Ja18-en-
coded interactions were mediated by the CDR1a and CDR3a,
respectively (approximately 18% versus 57% BSA, respec-
tively). Further, for all five complexes, the Vb8.2 interactions
were mediated solely via the CDR2b loop interacting with the
a1 helix of CD1d (approximately 24% BSA). This conserved
set of CDR2b-mediated interactions included Tyr48b and
Tyr50b interacting with Glu83 and Lys86 of CD1d, the latter of
which formed vdw interactions with Glu56b (Table S3). This is
comparable to what was previously observed for the NKT
TCR-CD1d-a-Galcer interaction.
For the NKT TCR-CD1d-a-GlcCer complex, the BSA was only
600 A˚, with the CDR1a-, CDR3a-, and CDR2b-mediated inter-
actions contributing 19%, 47%, and 33%BSA, respectively (Fig-
ure 5D). The lower BSAwas attributable to the increasedmobility
of the CDR3a loop within this complex, in which Leu99a was not
resolved in the electron density, and thus was not included in the
final refined model. In the NKT TCR-CD1d-a-GalCer complex,
Leu99a made specificity-governing contacts with Arg79 and
Val149 of CD1d (Table S3). Thus, the increased mobility of
Leu99a in the a-GlcCer complex would contribute toward the
lower affinity of this interaction.
To evaluate whether the five AGLs caused any structural
perturbations within CD1d, their respective CD1d Ag-binding
clefts were compared to the NKT TCR-CD1d-a-GalCer complex
and nonliganded counterparts if available (Figure 5G and not
shown). Minimal root-mean-square-deviations (rmsd) (range
Immunity
NKT TCR Fine Specificity0.26–0.33 A˚) were observed, indicating that the AGLs do not
noticeably alter the structure of the CD1d-Ag binding cleft
when ligated to the NKT TCR. Despite truncation and unsatura-
tion of the acyl tails of C20:2 and a-GlcCer, the first seven
carbons of their acyl tails adopted a similar conformation to
that observed in CD1d-a-GalCer. For CD1d-a-GalCer, the tip
of the 26C acyl tail curled back on itself to form stabilizing
intra-vdw interactions. Because only 7 of the 20 acyl tail carbons
were observed for the C20:2 ternary complex, it suggests
that this acyl chain lacks these stabilizing intra-van der Waal
(vdw) interactions and hence is mobile within the A0-pocket.
Nevertheless, the A0-pocket of CD1d, when bound to the
C20:2 and a-GlcCer, maintained a near-identical conformation
when compared to CD1d-a-GalCer. Previous studies involving
a-GalCer analogs with modifications on the acyl tails reported
the presence of a spacer lipid in the A0-pocket (Schiefner et al.,
2009); however, this was not observed in the NKT TCR-CD1d-
C20:2 and a-GlcCer complexes. We suggest that this is attribut-
able to the lengthier acyl chain analogs used in our studies,
which could be expected to sterically hinder the binding of
a spacer lipid.
Whereas the 400-deoxy modification on the sphingosine tail of
the 30,400-deoxy- and 40,400-deoxy a-GalCer AGLs did not affect
the conformation of CD1d-Ag binding cleft, the 30-OH on the
sphingosine tail shifted slightly (0.7 A˚) to accommodate for
this modification (Figure 6). The acyl and sphingosine chains of
the 30,400-deoxy- and 40,400-deoxy AGLs, when bound to CD1d,
adopted a similar conformation to that observed in the CD1d-
a-GalCer complex.
Within the NKT TCR-CD1d-OCH complex, a spacer lipid was
observed to occupy ‘‘the void’’ in the F0-pocket, essentially
mimicking the end of the sphingosine tail as observed in
CD1d-a-GalCer. However, the spacer lipid extended beyond
this limit such that it almost protruded out of the F0-pocket and
adopted a different conformation to the spacer lipid observed
in the binary mouse CD1d-OCH structure (Figure 5G; Sullivan
et al., 2010). Interestingly, when the OCH complex was
compared to a-GalCer complex, the truncated sphingosine tail
of OCH did not cause a repositioning of the F0-roof of CD1d
(not shown) (McCarthy et al., 2007; Sullivan et al., 2010).
However, a comparison of the CD1d-Ag binding clefts of the
binary CD1d-OCH complex (Sullivan et al., 2010) and the NKT
TCR-CD1d-OCH complex showed notable displacements
(>1 A˚) for Leu84, Val85, Lys86, Met87, Met88, and Val149.
Further, Leu84 and Leu150 in the binary CD1d-OCH structure
adopted very different conformations when compared to that
observed in the NKT TCR-CD1d-OCH complex (Figure 5G).
Although we cannot discount that these conformational differ-
ences between CD1d-OCH and NKT TCR-CD1d-OCH
complexes were attributable to the spacer lipid, our results
nevertheless indicated that the NKT TCR can operate via an
induced-fit mechanism, whereby the NKT TCR molds the F0-
pocket of the CD1d-Ag binding cleft to enable optimal
engagement.
The Basis of NKT TCR Fine Specificity
Three of the a-GalCer AGLs, for which structures were deter-
mined (a-GlcCer, 30,400-deoxy-, and 40,400-deoxy-a-GalCer),
contained glycosyl modifications—the only moiety of the CD1d-restricted Ag that is surface exposed and thus directly contacted
by theNKT TCR. TheC20:2 andOCHAGLs possessedmodifica-
tions in the acyl and sphingosine tails, respectively, and the inter-
action between the a-galactosyl head group of these latter two
AGLs and theNKT TCRwas essentially identical to that observed
in the NKT TCR CD1d-a-GalCer interaction (Figures 6A–6E).
Namely, for the C20:2 and OCH AGLs, the galactose ring sat
underneath the CDR1a loop and abuts the CDR3a loop, forming
vdw contacts on one face of the sugar ring with Arg95a, Gly96a,
and Pro28a. Arg95a also made vdw contacts with the 30-OH of
the sphingosine chain. Gly96a H-bonds to the 20-hydroxyl, while
Asn30a H-bonds to both the 30- and 40-OH groups of the galac-
tose ring (Figures 6C and 6E). Further, within the NKT TCR-
CD1d-OCH and C20:2 complexes, the CDR3a loop interacted
with mCD1d. Arg95a and Arg103a flanked Arg79 from CD1d,
and thesepositive chargesweredissipatedbyneighboring acidic
groups of Asp94a, Glu83, and Asp80 (Figure 6D). Collectively,
these CDR3a loop and CD1d residues provided a focused
network of polar and salt-bridging interactions.
As a direct result of modifications in the glycosyl head groups
of a-GlcCer, 30,400-deoxy-, and 40,400-deoxy-a-GalCer AGLs, the
interactions with the NKT TCRweremodified to varying degrees,
although there was no notable juxtapositioning in the side chain
conformations of the NKT TCR to compensate for these modifi-
cations (Table S3). In the NKT TCR-CD1d-30,400-deoxy-a-GalCer
AGL complex, the loss of the 30-OH resulted in a loss of a H-bond
to Asn30a from the CDR1a loop and the vdw contacts with
Gly96a of the CDR3a loop; in addition, a H-bond to Asp153 of
CD1d was lost that could potentially have an impact on the
stability of the CD1d-30,400-deoxy-a-GalCer complex (Figure 6F).
Collectively, the loss of these interactions also caused a slight
tilting of the galactosyl head group, such that a maximal
displacement of 0.7 A˚ with respect to the NKT TCR-CD1d-
C20:2 complex was observed at the 50-C position.
In the NKT TCR-CD1d-40,400-deoxy-a-GalCer AGL complex,
there was a greater shift of the galactosyl head group, with the
entire ring being displaced down toward CD1d by approximately
0.9 A˚. As a consequence, the lack of the 40-OHmoiety resulted in
a loss not only of an H-bond to Asn30a, but also of vdw contacts
between the 30-OH and CDR3a loop and a lengthening of the
H-bond between this 30-OH moiety and Asn30a (Figure 6G).
Similarly, in the NKT TCR-CD1d-a-GlcCer AGL complex, the
glucosyl head group was also displaced by approximately
0.9 A˚, but in this instance it repositioned along the roof of the
A0-pocket, which also resulted in the 30-OH moiety being too
far away to interact with Gly96a of CDR3a, as well as Asp153
of CD1d (Figure 6H). Within this complex, the 40-OH of the gluco-
syl ring pointed in a different direction to the 40-OH of the galac-
tosyl ring, resulting in a lost H-bond with Asn30a of the TCR and
formation of an H-bond to the main chain of Gly155 of CD1d.
Accordingly, the effects of modification of the 40-OH were
more marked than for the 30-OH, thereby providing a basis for
understanding the greater dependency of the 40-OH in NKT
TCR recognition.
The Contribution of TCRb Chain to AGL Recognition
We have previously identified differences in the NKT TCR-CD1d-
a-GalCer contacts depending on the use of Vb8.2 or Vb7 b chain
(Pellicci et al., 2009). We therefore wanted to explore NKT TCRImmunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc. 333
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study. The percentage of NKT cells expressing Vb7 or Vb8.1-
8.2 were analyzed after 3 days of in vitro proliferation in the pres-
ence of the different AGLs (Figures 7A–7B). Although all AGLs
tested were capable of activating both Vb7 and Vb8.1-8.2 NKT
cells, those with an altered 40-OH on the sugar (a-GlcCer,
a-GlcCer (C24), 40,400-deoxy-a-GalCer, and 40-deoxy-a-GalCer)
induced higher percentages of Vb7+ NKT cells than cultures
stimulated with a-GalCer, a-GalCer (C24), C20:2, and OCH.
We also determined the degree of Vb usage with cell division
by gating in individual cell division peaks (Figures 7B–7C and
data not shown). The bias toward Vb7 usage was dependent
on the altered glycosyl head group, as indicated by the fact
that both 40,400-deoxy-a-GalCer and 40-deoxy-a-GalCer showed
a Vb7 bias, whereas 400-deoxy a-GalCer did not. Similarly, both
a-GlcCer (C20:2) and a-GlcCer (C24) showed a Vb7 bias,
whereas a-GalCer (C24) and a-GalCer (C20:2) did not. Thus,
for AGLs with an altered 40-OH sugar moiety, especially
a-GlcCer, that Vb7+ NKT cells were progressively enriched
with each division cycle. Conversely, other AGLs, especially
OCH, resulted in a loss of Vb7+ NKT cells with each progressive
division cycle, a result that is consistent with an earlier study sug-
gesting that OCH is preferentially recognized by Vb8+ NKT TCRs
(Stanic et al., 2003). These data support the concept that AGLs
have a direct impact on NKT cell function not only at the level
of individual cells, but also at the population level where different
NKT cell clones may be engaged depending on their TCRb chain
usage. With this in mind, we engineered an NKT cell hybridoma
to express the same TCRb chain that was used in our SPR and
crystallography studies above. This hybridoma was challenged
with the AGLs presented by in vitro generated bone marrow
dendritic cells and the response measured by IL-2 production
after 24 hr (Figure 7D). These experiments showed a hierarchy
of IL-2 production that broadly reflected the affinity of the
different AGLs for this particular NKT TCR. Namely, C20:2 and
a-GalCer provided a clear IL-2 response at lower doses,
whereas a-GlcCer did not stimulate at the same lower doses
and, even at higher doses, it induced less IL-2 than a-GalCer
and C20:2, whereas 30,400-deoxy-a-GalCer, 40,400-deoxy-a-
GalCer, 40-deoxy-a-GalCer, and OCH showed responses that
were in between a-GalCer and a-GlcCer. This response was
also distinct from the proliferation hierarchy observed for freshly
isolated NKT cells (Figures 3A and 3B) but was largely consistent
with the proliferation of fresh NKT cells in response to glycolipids
presented by plate-bound CD1d (Figure 3C) and with the hier-Figure 5. Structure of the NKT TCR in Complex with Different a-GalCe
(A–F) Ribbon representation of the NKT TCR-CD1d-Ag structures with the corre
(A) NKT TCR in complex with CD1d-a-GalCer (Pellicci et al., 2009).
(B) NKT TCR-CD1d-OCH.
(C) NKT TCR-CD1d-C20:2.
(D) NKT TCR-CD1d-a-GlcCer.
(E) NKT TCR-CD1d-30,400-deoxy-a-GalCer.
(F) NKT TCR-CD1d-40,400-deoxy-a-GalCer.
Footprints are color-coded based on the CDR loop contributions. TCRa, cyan;
CD1d heavy chain, gray; b2m, dark gray; a-GalCer, magenta; C20:2, pink; a-GlcC
blue; spacer lipid, light green.
(G) NKT TCR induced fit of CD1d-OCHwithin the F0-pocket. Comparison of the bin
NKT TCR-CD1d-OCH complex (light blue; spacer lipid, light green). a-GalCer isarchy observed for the cytokine profiles derived from fresh
NKT cells (Figure 4).
DISCUSSION
NKT cells can recognize a variety of CD1d-restricted glycolipid
Ags, yet can discriminate between closely related CD1d-
restricted ligands (reviewed in Godfrey et al., 2010; Venkatasw-
amy and Porcelli, 2010). a-GalCer is a clinicial trial phase I
therapeutic of which many derivatives have been synthesized
with a view to modulate the NKT cell response (reviewed in Ven-
kataswamy and Porcelli, 2010). There is great interest in the
ability of AGLs to modulate the NKT cell response, although
the molecular basis for such effects remains unclear. Various
explanations for the differential effects of AGLs on NKT cell func-
tion include differing affinities, pharmacokinetics, and involve-
ment of different APCs; distinct CD1d loading kinetics; and
distinct intracellular processing and presentation on the cell
surface (Im et al., 2009; Sullivan et al., 2010; Venkataswamy
and Porcelli, 2010). Our study has formally demonstrated the
structural and biophysical basis for NKT TCR fine specificity
against a set of closely related glycosylceramide analogs, which
we have termed altered glycolipid ligands (AGLs). We have also
related these molecular and biochemical observations to the
NKT cell proliferative response, cytokine production, and NKT
TCR Vb usage. We selected ten AGLs, thereby gaining a broad
perspective on the range of effects such modifications could
impact on the structural and functional aspects of the NKT
response.
In MHC-restricted immunity, subtle alterations of the antigenic
peptide canmarkedlymodulate the immune response. However,
despite the dramatically different biological outcomes such
APLs can elicit, only slight conformational readjustments are
observed at the TCR-pMHC interface (Baker et al., 2000; De-
gano et al., 2000). Our findings mirror the APL studies of the
MHC-restricted immune response, in that none of the AGLs
studied had a profound impact on the NKT TCR-CD1d-Ag inter-
action. In MHC-restricted immunity, neither the affinity nor the
half-life of the interaction has been an absolute predictor of
ligand potency (Sloan-Lancaster and Allen, 2003), leading to
other factors such as dwell-time, TCR-pMHC confinement
models, and aggregate t1/2 (ta) being proposed as more reliable
indicators of ligand potency (Aleksic et al., 2010; Govern et al.,
2010). To compound matters, recent studies have shown that
solution-based affinity measurements may not be fully reflectiver AGLs
sponding footprints shown underneath.
TCRb, green; CDR1a loop, purple; CDR3a loop, yellow; CDR2b loop, orange;
er, red; 30,400-deoxy-a-GalCer, brown; 40,400-deoxy-a-GalCer, blue; OCH, light
ary CD1d-OCH (Sullivan et al., 2010) (yellow; spacer lipid, cyan) with the ternary
shown in magenta.
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Figure 6. Comparison of the Glycosyl Head Group NKT TCR Interac-
tions
(A) a-GalCer.
(B) CDR3a loop interactions with CD1d-a-GalCer.
(C) C20:2.
(D) CDR3a loop interactions with CD1d-a-C20:2.
(E) OCH.
(F) 30,400-deoxy-a-GalCer.
(G) 40,400-deoxy-a-GalCer.
(H) a-GlcCer.
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of TCR-pMHC docking modes suggests that a unifying param-
eter defining ligand potency in MHC-restricted immunity may
prove challenging. In contrast, CD1d is monomorphic, the NKT
TCR is semi-invariant, and at present the mode of NKT TCR-
CD1d-Ag docking appears to be highly conserved. Thus, a priori,
affinity or t1/2 values may represent a more reliable indicator with
respect to NKT TCR ligand potency. A confounding issue relating
to CD1d-restricted Ags, however, is that modifications in the
lipid tails can impact on ligand potency indirectly, and this
certainly seems to be the case for AGLs with acyl chain modifi-
cations. Our data indicated that the altered potency arising
from acyl chain modifications can arise only from alterations in
Ag processing and presentation, as shown by the fact that
they impacted neither on the NKT TCR-CD1d-AGL interaction
nor on the affinity or kinetics of the interaction. Interestingly,
however, modifications within the sphingoid base, as exempli-
fied by the OCH AGL, impacted on the affinity of the interaction,
ostensibly by causing a slower on rate, indicative of an induced-
fit interaction, consistent with our structural data and recent
observations in NKT TCR recognition of a microbial ligand (Li
et al., 2010). This parallels similar observations in TCR-pMHC
recognition, whereby buried alterations (polymorphisms) within
the Ag-binding cleft of MHC can change the dynamics of the
pMHC complex, which in turn alter the affinity of the TCR inter-
action (Archbold et al., 2009; Tynan et al., 2007). Thus, although
the NKT TCR is considered to be relatively rigid (Borg et al.,
2007), it can nevertheless operate in an induced-fit manner by re-
shaping the CD1d-Ag landscape, which is speculated to occur
for the recognition of bulkier CD1d-restricted ligands such as
iGb3 (Florence et al., 2009).
Modifications of the glycosyl headgroup directly reduced
the t1/2 of the interaction, with the NKT TCR exhibiting greater
sensitivity for the 40-OH position of a-GalCer than for the
30-OH position. The 30-OH modification resulted solely in
a loss of interactions at this position, whereas modifications at
the 40-OH, as observed for the a-GlcCer and 40-deoxy AGLs,
altered the bonding network at both the 40 and 30 positions,
thereby providing a molecular basis for understanding the
greater sensitivity of the NKT TCR for the 40-OH position of
a-GalCer. These headgroup modifications resulted in reduced
NKT cell activation (cytokine production), compared to their
response to a-GalCer. Different AGLs may also drive expansion
of different NKT cell clones, depending on their TCRb chain
usage, which represents another means by which these ligands
may differentially influence NKT cell activation. For example,
the preferential Vb8 usage by NKT cells proliferating in response
to OCH further supports the notion that the NKT TCR-CD1d
interaction is finely tuned to subtle alterations within the
F0-pocket. Conversely, modifications to the 40-OH position of
the sugar (a-GlcCer and 40,400-deoxy a-GalCer) appeared to
favor the Vb7+ NKT cells, which were more highly represented
within more proliferated cells. These data indicate that theColors are as follows: CDR1a loop, purple; CDR3a loop, yellow; CD1d
a helices, gray; a-GalCer, magenta; C20:2, pink; OCH, light blue; spacer lipid,
light green; 30,400-deoxy-a-GalCer, brown; 40,400-deoxy-a-GalCer, blue;
a-GlcCer, red; site of modification to analogs, cyan. H-bonds shown as
dashed black lines.
A B
C
D
Figure 7. Vb7 Usage and the CD1d-AGLs
(A–C) CFSE- or eFluor 670-labeled thymocytes en-
riched for NKT cells were cultured for 3 days with
glycolipid-pulsed Tcra-Jtm1Tg (Ja18/)
splenocytes, and Vb expression of a-GalCer-
CD1d tetramer+ NKT cells was analyzed by flow
cytometry at distinct division cycles.
(A) An example of the approach to determine
the percentage of undivided or division 6 NKT cells
that were Vb7+ after culture in the presence of
glycolipid.
(B) Percentage of Vb7 or Vb8.1-8.2+ cells within
each division peak for three representative glyco-
lipids.
(C) Summary of results showing the percentage of
Vb7+ NKT cells within the most proliferated cells
(from the last major generation) from two to six
independent experiments.
(D) Dose-response analysis of an NKT cell
hybridoma, engineered to express the NKT TCR
used in SPR and crystallography studies (see
Experimental Procedures), stimulated overnight
with BMDCs plus the various AGLs at concentra-
tions from 125 nM to 125 pM. Each data
point represents the mean of triplicate IL-2 read-
ings ± SD from a single experiment. BMDCs
derived from Cd1d/ mice used in the same
conditions did not stimulate the hybridoma (data
not shown).
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dependent on the fine-specificity requirements of the NKT
TCR-CD1d interaction.
Our findings provide a molecular basis for our understanding
of how different AGLs can promote distinct responses by
CD1d-dependent NKT cells. Our findings simultaneously
provide a rational basis for the design of tailor-made NKT-based
therapeutics and a better understanding of the fine specificity of
the NKT TCR.
EXPERIMENTAL PROCEDURES
Glycolipid Ags
The glycolipid analogs used in this study were synthesized as previously
described (Jervis et al., 2010; Miyamoto et al., 2001; Raju et al., 2009; Yu et al.,
2005). See Supplemental Information for synthesis of 40-deoxy-a-GalCer.
Mice
C57BL/6 (B6) and Tcra-Jtm1Tg (Ja18/) (obtained from M. Taniguchi, RIKEN,
Yokohama, Japan, and backcrossed 10 times to B6 background) mice were
maintained under SPF conditions in the animal facilities of the Department of
Microbiology and Immunology, The University of Melbourne. All experiments
involving mice were approved by the University of Melbourne animal ethics
committee and performed in accordance with ethics guidelines regarding
the proper handling of animals.
CFSE Labeling and Proliferation Assay
Splenocytes from Tcra-Jtm1Tg mice (Ja18/) were pulsed overnight with
glycolipid in the presence of IL-2 at 100 U/ml. Cells were harvested and
overlayed on FCS, then centrifuged and resuspended in freshmedia to remove
excess glycolipid. Thymocytes were enriched for NKT cells by complementdepletion of anti-HSA- and anti-CD8-labeled cells. Dead cells were removed
with Histopaque (Sigma) gradient centrifugation. Thymocytes were labeled
with either 2 mM 5-,6-carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Molecular Probes) or 5 mM eFluor 670 (eBiosciences) and incubated for
10 min at 37C. Splenocytes and thymocytes were then combined at a ratio
of 2:1 and cultured in 96-well flat-bottom plates. For proliferative analysis, cells
were harvested after 72 hr and stained with anti-TCRb (BD Biosciences) and
a-GalCer (PBS-44)-loaded CD1d tetramer. For Vb analysis, cells were
harvested after 72 hr and stained with either anti-Vb7 or Vb8.1-8.2 (BD Biosci-
ences) and a-GalCer-loaded CD1d tetramer. Generational divisions of prolifer-
ating NKT cells were determined with FlowJo software (Treestar).
Cytokine Measurements
With similar stimulation conditions to the proliferation assay, IFN-g production
was analyzed by ICSon cells incubatedwithGolgistop (BDBiosciences) for the
last 4 hr of an 8 hr culture. Cells were surface stained, fixed, and permeabilized
(Cytofix-Cytoperm Kit, BD Biosciences) prior to staining with either anti-IFN-g-
phycoerythrin or anti-IFN-g-allophycocyanin. Culture supernatants were
collected after 8 hr and analyzed with CBA flex set for mice (BD Biosciences).
Protein Expression, Purification of the NKT TCR and CD1d
Cloning, expression, and purification of the mouse NKT TCR (Va14-Ja18;
Vb8.2) used in this study has been previously described (Pellicci et al.,
2009). Cloning, expression, purification, and loading of the mouse CD1d
protein were performed as described previously (Matsuda et al., 2000; Pellicci
et al., 2009).
Ternary Complex Purification, Crystallization,
Structure Determination, and Refinement
Purified mouse NKT TCR and CD1d-glycolipids were mixed and the ternary
complexes were isolated by gel filtration on a Superdex 200 10-300 column,
concentrated to 8mg/ml in 10mMTris (pH 8.0), and 150mMNaCl. Large crys-
tals grew in 22% polyethylene glycol 400, 0.1M ammonium acetate, and 0.1MImmunity 34, 327–339, March 25, 2011 ª2011 Elsevier Inc. 337
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Melbourne and processed and refined with standard software packages
(see Supplemental Information).
Surface Plasmon Resonance Measurements and Analysis
The interaction between soluble NKT TCR and the CD1d-glycolipid complexes
was analyzed by SPR with a Bio-Rad ProteOn XPR36 instrument (Hercules,
CA) essentially as described previously (Pellicci et al., 2009).
Cell Lines and Retroviral Packaging
TCRa and TCRb constructs were cloned into retroviral plasmids and ex-
pressed by retroviral transduction of the 5KC-78.3.20 TCRa- and TCRb-nega-
tive hybridoma, as previously described (Scott-Browne et al., 2007).
Hybridoma Stimulation
A total of 5 3 104 hybridomas were cultured for 20 hr with 5 3 104 BMDCs, in
complete RPMI medium containing 10% FCS, with the indicated concentra-
tion of AGLs. BMDCs were generated from single-cell suspensions from
femurs and tibia of C57BL/6 mice or CD1d/ mice and cultured for 6 days
in RPMI medium containing 10% FCS and 0.25% B78hi-conditioned medium
(B78hi is a cell line that produces GMCSF). Hybridoma responses were
measured by IL-2 ELISA in accordance with standard protocols.
Plate-Bound CD1d Stimulation Assay
Soluble mouse CD1d was loaded overnight with glycolipids at a 1:3 molar
ratio, and flat-bottom 96-well plates were then coated with 60 ml of 10, 1, or
0.1 mg/ml CD1d-glycolipid solution for 3 hr at 37C and then washed twice.
MACS-anti-PE-beads were used to enrich CD1d tetramer-PE-labeled thymic
NKT cells (95% pure) that were CFSE labeled and 23 104 added to each well.
After 48 hr, cells were placed into fresh (uncoated) plates to remove stimulus,
and at 72 hr, cells were analyzed by flow cytometry and cytokines in culture
supernatant were analyzed by CBA.
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